

New!
An Innovative Journal for
the Rapid Dissemination of
Important, Timely Research

Editor-in-Chief

Alan C. Sartorelli

Yale Comprehensive
Cancer Center
Yale University School of
Medicine

Editor

Barbara Z. Renkin


Department of Pharmacology
Yale University School of
Medicine

Associate Editor

William N. Hait

Department of Pharmacology
Yale University School of
Medicine

**Cancer
Communications**
Volume 1, Number 1, 1989



Pergamon Press

CALL FOR PAPERS

**Cancer
Communications**

publishes in English the
results of original
experiments in areas of
basic cancer research.

Procedures using
telecommunications,
floppy disks, electronic
mail, and paper
communication, have
been developed by the
Journal. The goal is to
have manuscripts
reviewed, proofed, and
published within ten
weeks, disregarding
time for revisions.

Cancer

Communications,

published monthly, is a new international
electronically published journal. It is designed to
promote the rapid dissemination of timely and
significant observations. Edited by distinguished
experts in the field, **Cancer Communications** will
publish high-quality research in areas of:

- Molecular biology;
- Biochemistry;
- Genetics;
- Endocrinology;
- Cell Biology;
- Biophysics;
- Virology and
- Immunology

that deal with fundamental aspects of cancer.
In-depth studies on the mechanism of action of
carcinogens and therapeutic agents will also be
featured.

The newest technologies in all phases of the
reviewing and publishing process will be utilized.

For complete, detailed instructions for the
preparation and transmittal of manuscripts, please
contact your nearest Pergamon office.

SUBSCRIPTION INFORMATION

ISSN: 0955-3541

Published 12 issues per annum

Professional Rate (1989)

US\$ 60.00

Annual Institutional Rate (1989)

US\$180.00

Two-Year Rate (1989/90)

US\$342.00

Free Sample Copy Available Upon Request

Prices include postage and insurance. Dollar prices quoted
apply in North and South America only. For subscription rates
in the rest of the world apply to the nearest Pergamon office.
Advertising rate card available upon request. To order, or for
more information, please contact:



Pergamon Press

A Member of the Maxwell Communication Corporation Group of Companies

US: Maxwell House, Fairview Park, Elmsford, NY 10523

UK: Headington Hill Hall, Oxford OX3 0BW, England

If you prescribe:



Vincristine
Vinblastine
Colchicine
Doxorubicin
Daunorubicin
Dihydroxyanthracenedione
Mitoxantrone
Mithramycin
Actinomycin D
Puromycin
Etoposide
Tenoposide
Emetine
Mitomycin
Gramicidin D
Ethidium bromide
Taxol
Cytochalasin B
1-Dehydrotestosterone
Glucocorticoids
Procaine
Tetracaine
Lidocaine
Propranolol



You need to know about:

Investigational Centocor P-glycoCHEK™ C219

The chemotherapeutics and other drugs listed at left have been associated with multidrug resistance (MDR).¹

MDR is a major obstacle to effective cancer chemotherapy. Data suggest that MDR is associated with elevated levels of P-glycoprotein, a cell membrane protein that may act as a "pump" to remove chemotherapeutic drugs from the cell.²

Many researchers believe that the higher the level of P-glycoprotein, the greater the drug resistance.³ Which is why you need to know about investigational P-glycoCHEK™ from Centocor.

P-glycoCHEK C219™ is a fluorescein-labeled monoclonal antibody that directly measures P-glycoprotein through fluorescence flow cytometry and microscopy.

Some of the conditions shown to be associated with elevated P-glycoprotein levels are:

- ▶ Leukemia⁴
- ▶ Breast cancer⁶
- ▶ Ovarian cancer⁵
- ▶ Colon cancer⁷

Available for investigational use. Physicians can now evaluate P-glycoCHEK in their patient population as a possible means of determining levels of P-glycoprotein in order to:

- ▶ Optimize treatment protocols
- ▶ Predict therapeutic responsiveness
- ▶ Identify candidates for alternative therapeutic approaches.

1. Morrow CS, Cowan KH: *Oncology* 2;10: 55-62 (1988).
2. Pastan I, Gottesman M: *N Engl J Med* 316: 1388-1393 (1987).
3. *Cope* November: 30 (1988).
4. Ma DDF, et al: *Lancet* 1:135-137 (1987).
5. Bell DR, et al: *J Clin Oncol* 3:311-315 (1985).
6. Dalton WS, et al: *Cancer Res* 48:1882-1888 (1988).
7. Fuqua SAW, et al: *Cancer Res* 47:2103-2106 (1987).

Please send me educational and order information on:

- ☐ Investigational P-glycoCHEK C219 for flow cytometry and microscopy.
- ☐ The unlabeled C219 antibody for research use in Western blotting, immunohistopathology and immunoprecipitation.

Name _____

Specialty _____

Address _____

Phone (____) _____

Name of the lab you are currently using _____

PLEASE RETURN TO THE APPROPRIATE ADDRESS BELOW.

© Copyright 1989 Centocor, Inc.

For Investigational Use Only. The performance characteristics of this product have not been established.



CENTOCOR DIAGNOSTICS
A Division of Centocor, Inc.